Pacira BioSciences grew its full-year 2019 revenues 25 percent from 2018, hitting $421 million.
What you should know:
1. For the fourth quarter, Pacira reported $122.4 million in revenues.
2. Exparel, Pacira's flagship drug, drove fourth-quarter and full-year sales, posting $116.9 million and $407.9 million, respectively.
3. The company posted a net loss on the quarter and year of $4.9 million and $11 million, respectively.
4. Pacira issued its 2020 outlook, predicting full-year revenues between $485 million and $500 million.
Pacira CEO David Stack said: "Demand has continued to mount within the anesthesia community as Exparel-based nerve and field blocks take hold as institutional protocol. Additionally, we enhanced our non-opioid pain management product portfolio with the addition of iovera and we are seeing great interest from the marketplace around this innovative system."
More articles on surgery centers:
PE-backed Prism Vision snags Maryland eye group — 4 insights
Florida ASC buyer projects $18M profit in 1st year: 5 details
Physician-owned eye group acquires California practice